MORPHOSYS Share Price Swiss Exchange
Equities
OXMOR
DE0006632003
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.38 EUR | 0.00% | 0.00% | 0.00% |
12:32pm | Morphosys says takeover by Novartis on course after report of drug safety concern | RE |
11/04 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
Sales 2024 * | 252M 270M 22.5B | Sales 2025 * | 325M 348M 29.07B | Capitalization | 2.56B 2.74B 229B |
---|---|---|---|---|---|
Net income 2024 * | -182M -195M -16.28B | Net income 2025 * | -115M -123M -10.29B | EV / Sales 2024 * | 9.74 x |
Net cash position 2024 * | 106M 114M 9.48B | Net cash position 2025 * | 241M 258M 21.52B | EV / Sales 2025 * | 7.12 x |
P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-32.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.59% |
Latest transcript on MORPHOSYS
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 01/19/01 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 07/23/07 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 17/18/17 |
Director/Board Member | 67 | 17/18/17 | |
Marc Cluzel
CHM | Chairman | 69 | 31/12/31 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+48.32% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MOR Stock
- OXMOR Stock